Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours

Oncology Letters

Volumn 3, Issue 3, 2012, Pages 677-681

  Nannini, Margherita ^a   Pantaleo, Maria Abbondanza ^a,b   Maleddu, Alessandra ^a   Saponara, Maristella ^a   Mandrioli, Anna ^a   Lolli, Cristian ^a   Pallotti, Maria Caterina ^a   Gatto, Lidia ^a   Santini, Donatella ^a   Paterini, Paola ^b   Scioscio, Valerio Di ^c   Satena, Fausto ^a   Fusaroli, Pietro ^d   Pinna, Antonio Daniele ^a   Tos, Angelo Paolo Dei ^e   Biasco, Guido ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Interdepartmental Centre for Cancer Research 'G Prodi   (Italy)

^c University Hospital S   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e General Hospital of Treviso   (Italy)

Author keywords

Adjuvant therapy; Discontinuation; Gastrointestinal stromal tumours; Imatinib; KIT; Platelet derived growth factor receptor; Tyrosine kinase inhibitors

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MEDICAL RECORD REVIEW; METASTASIS; METASTASIS RESECTION; OVERALL SURVIVAL; PERITONEUM METASTASIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TUMOR RECURRENCE;

EID: 84855811358     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.537     Document Type: Article

References (22)

1. Demetri GD, von Mehren M, Blanke CD, van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002.
2. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373: 1097-1104, 2009.
3. Joensuu H, Eriksson M, Hatrmann J, Sundby Hall K, Schutte J, Reichardt M, Schlemmer M, Wardelmann E, Ramadori G, Al-Batran S, et al: Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recur- rence: final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol 29 (Suppl): LBA1, 2011.
4. Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, et al; French Sarcoma Group: Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11: 942-949, 2010.
5. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, et al: Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25: 1107-1113, 2007.
6. Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Sohn HJ, Lee JS and Kang YK: Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response. Jpn J Clin Oncol 36: 704-711, 2006.
7. Casali PG and Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts: Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v98-v102, 2010.
8. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH and Weiss SW: Diagnosis of gastroin- testinal stromal tumors: a consensus approach. Hum Pathol 33: 459-465, 2002.
9. Miettinen M and Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23: 70-83, 2006.
10. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, et al: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182-4190, 2005.
11. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, et al; Intergroupe Français des Leucémies Myéloïdes Chroniques: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029-1035, 2010.
12. von Mehren M, Heinrich M, Joensuu H, Blanke CD, Wehrle E and Demetri GD: Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). J Clin Oncol 29 (Suppl): 10016, 2011.
13. Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, Fiore M, Hohenberger P and Gronchi A: Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 21: 403-408, 2010.
14. Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S and Casali PG: Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/ metastatic GIST. Ann Surg 245: 341-346, 2007.
15. Hohenberger P, Schneider U, Pink D, Emmerich K, Kettelhack C, Roetschke O and Reichardt P: Resection of progressive or residual tumor after treatment with imatinib for advanced GI stromal tumors. Ann Surg Oncol 11 (Suppl): 53, 2004.
16. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF and Antonescu CR: Results of tyrosine kinase inhibitor therapy followed by surgical resection of metastatic gastrointestinal stromal tumor. Ann Surg 245: 347-352, 2007.
17. Bonvalot S, Eldweny H, Péchoux CL, Vanel D, Terrier P, Cavalcanti A, Robert C, Lassau N and Cesne AL: Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 13: 1596-1603, 2006.
18. Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, Krawczyk M and Ruka W: Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 93: 304-311, 2006.
19. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD and Bertagnolli MM: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24: 2325-2331, 2006.
20. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, et al: Adjuvant chemo-therapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26: 4906-4911, 2008.
21. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD): Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007-1016, 2008.
22. Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH and DeMatteo RP: Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 10: 1045-1052, 2009.